Completed OBSERVATIONAL NCT00233649

DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

Sponsor: AstraZeneca

Conditions Crestor, Rosuvastatin Diabetes Mellitus Type 2 LDL Cholesterol Observational

Updated 8 times since 2017 Last updated: Nov 18, 2010 Started: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Crestor, Rosuvastatin and Diabetes Mellitus Type 2 and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed
Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's Gravenmoer, Netherlands , 's-Hertogenbosch, Netherlands , Aalten, Netherlands , Alkmaar, Netherlands , Almelo, Netherlands , Alphen aan den Rijn, Netherlands , Amersfoort, Netherlands , Ammerzoden, Netherlands , Amstelveen, Netherlands , Amsterdam, Netherlands and 212 more locations